Dermatología Revista Mexicana

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor


>Revistas >Dermatología Revista Mexicana >Año 2015, No. 5

Guzmán-Sánchez DA
Alopecia androgenética
Dermatología Rev Mex 2015; 59 (5)

Idioma: Español
Referencias bibliográficas: 52
Paginas: 387-394
Archivo PDF: 718.31 Kb.

Texto completo


En el mundo, la alopecia androgenética es uno de los tipos de alopecia no cicatricial más frecuente; afecta a 45% de los hombres y hasta 10% de las mujeres de la población general. En este artículo se revisarán la causa, cuadro clínico, diagnóstico y tratamiento actual de esta enfermedad.

Palabras clave: alopecia, alopecia androgenética, alopecia de patrón femenino, minoxidil, finasterida.


  1. Sperling L, Sinclair R, El Shabrawi, Caelen L. Alopecias. In: Bolognia JL, Jorizzo JL, Schaffer J. Dermatology text book. 3rd ed. London: Mosby Elsevier, 2012;1093-1114.

  2. Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol 2012;67:1040-1048.

  3. Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol 2014;149:15-24.

  4. Ludwig E. Die androgenetische alopecia bei der Frau. Arch Klin Exp Dermatol 1964;219:558-564.

  5. Atanaskova Mesinkovska N, Bergfeld WF. Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin 2013;31:119-127.

  6. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Invest Dermatol Symp Proc 2005;10:184-189.

  7. Yip L, Rufaut N, et al. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australas J Dermatol 2011;52:81-88.

  8. Yip L, et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 2009;161:289-294.

  9. Keene S. Goren A. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatol Ther 2011;24:296-300.

  10. Zhuo FL, et al. Androgen receptor gene polymorphisms and risk for androgenetic alopecia: a meta-analysis. Clin Exp Dermatol 2012;37:104-111.

  11. Oh H-S, Smart RC. An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation. Proc Natl Acad Sci USA 1996;93:12525-12530.

  12. Chanda S, et al. 17beta-estradiol and ICI-182780 regulate the hair follicle cycle in mice through an estrogen receptor-alpha pathway. Am J Physiol Endocrinol Metab 2000;278:202-210.

  13. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav 2012;62:263-271.

  14. Arias-Santiago S, et al. Androgenetic alopecia and cardiovascular risk factors in men and women: A comparative study. J Am Acad Dermatol 2010;63:420-429.

  15. Arias-Santiago S, et al. Sex hormone-binding globulin and risk of hyperglycemia in patients with androgenetic alopecia. J Am Acad Dermatol 2011;65:48-53.

  16. Lo Sicco K, McGuire S, English JC 3rd. A retrospective study of thyroid structural abnormalities in alopecia patients. Dermatoendocrinol 2011;3:251-254.

  17. 16a. Su LH, Chen LS, Chen HH. Factors associated with female pattern hair loss and its prevalence in Taiwanese women: A community-based survey. J Am Acad Dermatol 2013;69:69-77.

  18. Su LH, Chen LS, Lin SC, Chen HH. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease. JAMA Dermatol 2013;149:601-606.

  19. Savin RC. Evaluating androgenetic alopecia in male and female patients. Kalamazoo, Mi: The Upjohn Compan, 1996;35:770-776.

  20. Yip Y, Sinclair RD. Antiandrogen therapy for androgenetic alopecia. Exp Rev Dermatol 2006;1:261-269.

  21. Van Zuuren EJ, Fedorowicz Z, Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol 2012;167:995-1010.

  22. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011;65:1126-1134.

  23. Mella JM, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010;146:1141-1150.

  24. Yeon JH, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 2011;25:211-214.

  25. Hamilton JB. Patterned hair loss in man; types and incidence. Ann N Y Acad Sci;1951:53:708-728.

  26. Wang TL, et al. Prevalence of androgenetic alopecia in China: a community- based study in six cities. Br J Dermatol 2010;162:843-847.

  27. Cobb JE, et al. Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. Exp Dermatol 2010;19:1026-1028.

  28. Heilmann S, et al. Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol 2013;133:1489-1496.

  29. Mumcuoglu C, Ekmekci TR, Ucak S. The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia. Eur J Dermatol 2011;21:79-82.

  30. Arias-Santiago S, et al. Androgenetic alopecia as an early marker of benign prostatic hyperplasia. J Am Acad Dermatol 2012;66:401-408.

  31. Amoretti A, Laydner H, Bergfeld W. Androgenetic alopecia and risk of prostate cancer: a systematic review and metaanalysis. J Am Acad Dermatol 2013;68:937-943.

  32. Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol 2011;37:27-32.

  33. Rossi A, et al. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups:10 year follow-up. Dermatol Therapy 2011;24:455-461.

  34. Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg 2011;37:1351-1354.

  35. Banka N, Bunagan MJ, Shapiro J. Pattern hair loss in men: diagnosis and medical treatment. Dermatol Clin 2013;31:129-140.

  36. Bunagan MJ, Banka N, Shapiro J. Hair transplantation update: procedural techniques, innovations, and applications. Dermatol Clin 2013;31:141-153.

  37. Kim H, Choi JW, Kim JY, Shin JW, et al. Low-level light therapy for androgenetic alopecia: a 24-week, randomized, doubleblind, sham device-controlled multicenter trial. Dermatol Surg 2013;39:1177-1183.

  38. Famenini S, Goh C. Evidence for supplemental treatments in androgenetic alopecia. J Drugs Dermatol 2014;13:809-812.

  39. Fischer TW, Trüeb RM, Hänggi G, Innocenti M, Elsner P. Topical melatonin for treatment of androgenetic alopecia. Int J Trichology 2012;4:236-245.

  40. Le Floc’h C, Cheniti A, Connétable S, Piccardi N, et al. Effect of a nutritional supplement on hair loss in women. J Cosmet Dermatol 2015;14:76-82.

  41. D’Agostini F, et al. Chemoprevention of doxorubicin-induced alopecia in mice by dietary administration of L-cystine and vitamin B6. Arch Dermatol Res 2013;305:25-34.

  42. Obrigkeit DH, Oepen T, Jugert FK, Merk HF, Kubicki J. Xenobiotics in vitro: the influence of L-cystine, pantothenat, and miliacin on metabolic and proliferative capacity of keratinocytes. Cutan Ocul Toxicol 2006;25:13-22.

  43. Kwack MH, Ahn JS, Kim MK, Kim JC, Sung YK. Preventable effect of L-threonate, an ascorbate metabolite, on androgen- driven balding via repression of dihydrotestosteroneinduced dickkopf-1 expression in human hair dermal papilla cells. BMB Rep 2010;43:688-692.

  44. Fischer TW. The influence of melatonin on hair physiology. Hautarzt 2009;60:962-972.

  45. Gopaul R, Knaggs HE, Lephart ED. Biochemical investigation and gene analysis of equol: a plant and soy-derived isoflavonoid with antiaging and antioxidant properties with potential human skin applications. Biofactors 2012;38:44-52.

  46. McElwee KJ, et al. Dietary soy oil content and soy-derived phytoestrogen genistein increase resistance to alopecia areata onset in C3H/HeJ mice. Exp Dermatol 2003;12:30-36.

  47. Falto-Aizpurua L, Choudhary S, Tosti A. Emerging treatments in alopecia. Expert Opin Emerg Drugs 2014;19:545-556.

  48. Daniells S, Hardy G. Hair loss in long-term or home parenteral nutrition: are micronutrient deficiencies to blame? Curr Opin Clin Nutr Metab Care 2010;13:690-697.

  49. Finner AM. Nutrition and hair: deficiencies and supplements. Dermatol Clin 2013;31:167-172.

  50. Pérez-Mora N, Goren A, Velasco C, Bermudez F. Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications. Dermatol Ther 2014;27:159-162.

  51. Collin C, Gautier B, Gaillard O, Hallegot P, et al. Protective effects of taurine on human hair follicle grown in vitro. Int J Cosmet Sci 2006;28:289-298.

  52. Kim H, Chang H, Lee DH. Simulative evaluation of taurine against alopecia caused by stress in Caenorhabditis elegans. Adv Exp Med Biol 2013;776:267-276.

  53. Zhang HH, Jiang QK, Sun WL, Xu C, et al. Effects of different dietary protein levels and DL-methionine supplementation on hair growth and pelt quality in mink (Neovision vision). J Anim Physiol Anim Nutr (Berl) 2013;97:1036-1042.

>Revistas >Dermatología Revista Mexicana >Año2015, No. 5

· Indice de Publicaciones 
· ligas de Interes 

Derechos Resevados 2019